Verschueren et al. reported 10.0 months for PD-L1 <1%, 19.9 months for 1–49% and 26.2 months for ≥50% [12], while Waterhouse et al. reported 10.2 months for PD-L1 <1%, 11.8 months for 1–49% and 19.1 months for ≥50% NSQ NSCLC [13]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.